Back to overview

Clinitude expands to Limburg

International pharma player Clinitude is expanding its European arm to Limburg. POM Limburg is bringing the company to the future Health Campus in Diepenbeek. This year, Clinitude will hire an additional 35 highly skilled profiles, some of whom will be recruited in Limburg.

The Leuven-based CRO – Clinical Research Organisation – Clinitude conducts clinical studies for pharmaceutical companies and specializes in research on vaccines and radioactive products. In addition to its headquarters in Leuven, the company has branches in Singapore, the Philippines, and the United States. It currently employs around 50 people. Chairman Tom Vandeput said, “After Amador Bioscience and Anima Research Center, the Welkommanagement team of POM Limburg is once again bringing a promising pharma player to Limburg. This contributes to the growing attractiveness of the Health Campus, both nationally and internationally. Our ambition is to become a global player in healthcare, and we are clearly on the right path.”

Clinitude aims to double its revenue this year and is still looking to hire 35 highly skilled profiles. Some of these positions will be filled in Limburg. CEO Sabrina Wijnen said, “By choosing Limburg for our further expansion, we are returning to our roots. In Limburg, there are many professionals working in our sector, but most of them commute to Brussels or Antwerp. We hope to attract some of these profiles with our move to Limburg. Since I strongly believe in an ecosystem, it is only logical that Clinitude wants to diversify in the Belgian Limburg ‘clinical research’ landscape.”

The proximity of UHasselt is an additional advantage for growing pharma companies. This allows them to recruit talent at the source. Piet Stinissen, Dean of Medicine and Life Sciences at UHasselt, said, “We are pleased with Clinitude’s arrival at the Health Campus. The company strengthens our regional healthcare ecosystem and offers great opportunities for our graduates in sectors such as healthcare and biomedicine. The presence of Clinitude will also create additional opportunities for the clinical scientific research that we are developing together with our Limburg partner hospitals.”

The announced arrival of pharma consultant Amador Bioscience in Limburg plays an essential role in attracting new companies. Amador is among the top three worldwide in clinical studies. Tom Vandeput said, “A company like Amador has a magnetic effect on other major players who want to collaborate with them. This is also what we have in mind for the Health Campus: the development of a strong healthcare ecosystem in Limburg, with space for education, research, and businesses.” While awaiting the new building complex on the Health Campus, Clinitude will temporarily occupy offices at Corda Campus. The first building of the new campus is set to open its doors in 2023.


  • (Optional)
  • This field is for validation purposes and should be left unchanged.

We use cookies or similar technologies (e.g. pixels or social media plug-ins) to optimise your user experience on our website, among other things. In addition, we wish to use analytical and marketing cookies to personalise your visit to our website, to send targeted advertisements to you, and to give us more insight into your use of our website.

Do you consent to our use of cookies for an optimal website experience, so that we can improve our website and surprise you with advertisements? Then confirm with ‘OK’.

Conversely, would you like to set specific preferences for different types of cookies? This can be done via our Cookie Policy. Would you like more information about our use of cookies or how to delete cookies? Please read our Cookie Policy.